CCNE1 degrader-2
CCNE1 degrader-2 is an orally active CCNE1 degrader with a paDC50 of 7.7 nM. CCNE1 degrader-2 promotes the targeted degradation of Cyclin E1 protein. CCNE1 degrader-2 inhibits tumor cell proliferation and exerts antitumor activity in CDX in vivo models. CCNE1 degrader-2 is used in research on cancers such as ovarian cancer and breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 3133169-21-5
- Formula: C30H27FN4O5
- Molecular Weight:542.56
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
CCNE1 |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
CCNE1 degrader-2 (3-30 mpk PO BID; 28 days) exhibits dose-dependent tumor growth inhibition at all tested doses in the HCC1569 breast cancer CDX mouse model and the OVSAHO ovarian cancer CDX mouse model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female Balb/c nude mice were subcutaneously inoculated on the right flank with 1 × 107 MKN1 cells in 0.1 mL of RPMI‑1640 and Matrigel (1:1 ratio)[1]
-
Dosage:30 mpk
-
Administration:Oral (PO) administration; twice daily; for 21 days
-
Result:Significantly inhibited tumor growth and reduced CCNE1 protein levels.
-
Animal Model:Female NOD/SCID mice were subcutaneously inoculated on the right flank with 2 × 106 HCC1569 cells in 0.1 mL of PBS and Matrigel (1:1 ratio)[1]
-
Dosage:3, 10, 30 mpk
-
Administration:Oral (PO) administration; twice daily; for 28 days
-
Result:Exhibited dose‑dependent tumor growth inhibition.
-
Animal Model:Female NOD/SCID mice were implanted with one estradiol pellet (0.36 mg/60‑day release) in the left flank two days prior to cell inoculation, then subcutaneously inoculated on the right flank with 1×107 OVSAHO cells in 0.2 mL of RPMI‑1640 and Matrigel (1:1 ratio)[1]
-
Dosage:3, 10, 30 mpk
-
Administration:Oral (PO) administration; twice daily; for 28 days
-
Result:Significantly suppressed tumor growth.
- BrdU Incorporation Assay
- Somatic Cell Culture
- CFSE Dye Dilution Proliferation Assay
- Dye-dilution cell tracking and proliferation staining
- CCK-8/WST-8 Cell Proliferation Assay
- Protocol for Cell Cycle
- Cell Counting-Based Growth Curve Assay
- Colony Formation (Clonogenic) Assay
- Breast Cancer Modeling
- Cell Viability Determination by MTT Colorimetric Assay
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Ki-67 Immunostaining Proliferation Assay
- PCNA Immunodetection Proliferation Assay
- Protocol for Cell Counting and Cell Density Analysis
- MTT Cell Proliferation Assay
- Subcutaneous Cell-Line-Derived Xenograft
Chemical Information
-
CAS No. 3133169-21-5
-
Molecular Weight 542.56
-
Formula C30H27FN4O5
-
SMILES
O=C1N(C2C(NC(CC2)=O)=O)CC3=CC=C(N4[C@H](CN(C5=CC=C(C=C5)OC6=CC=C(C=C6)F)C(C4)=O)C)C=C31
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CCNE1 degrader-2 Related Classifications
HY-189497 Related Classifications
Powered by Bioz